BioNTech SE (BNTX)

Etorro trading 970x250
BioNTech SE (BNTX) Logo

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131

BioNTech SE News and around…

Latest news about BioNTech SE (BNTX) common stock and company :

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
16 Aug, 2022 Yahoo! Finance

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Merck Jumps Into a $3.7 Billion mRNA Collaboration
16 Aug, 2022 Yahoo! Finance

Merck has been a laggard in the Covid-era race for messenger RNA technology, but it just announced a deal with privately held Orna Therapeutics.

A Look Into Healthcare Sector Value Stocks
15 Aug, 2022 FinancialContent

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing ...

U.K. regulator is first to authorize Moderna’s bivalent COVID booster for adults aged 18 and older
15 Aug, 2022 FinancialContent

The U.K. regulator has become the first to authorize Moderna's bivalent COVID vaccine booster for use in adults aged 18 and older.

U.K. regulator is first to authorize Moderna’s bivalent COVID booster for 18-and-older population
15 Aug, 2022 Yahoo! Finance

The U.K. regulator has become the first to authorize Moderna's bivalent COVID vaccine booster for use in adults aged 18 and older.

1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
15 Aug, 2022 FinancialContent

Pfizer's diversified portfolio of medicines will ensure it keeps outperforming BioNTech.

Pfizer CEO tests positive for COVID-19
15 Aug, 2022 Yahoo! Finance

MARKET PULSE Pfizer Inc. (pfe) CEO Albert Bourla tested positive for COVID-19. He tweeted Monday that he received four shots of the COVID-19 vaccine the company developed with BioNTech SE (bntx) is "experiencing very mild symptoms" and has started taking Paxlovid, Pfizer's COVID-19 antiviral.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
15 Aug, 2022 Yahoo! Finance

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Landmark Drug Pricing Reform Bill Passes Congress House
15 Aug, 2022 FinancialContent

The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for ...

Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
12 Aug, 2022 Yahoo! Finance

Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

Pharmaceutical Companies Report Gearing Up To Combat COVID Variants This Fall
11 Aug, 2022 FinancialContent

The more contagious omicron BA.4 and BA.5 COVID-19 variants are dominant in all parts of the United States, making up more than 70% of ...

Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
11 Aug, 2022 FinancialContent
Is This Battered Growth Stock Still a Buy After Its Latest Stumble?
11 Aug, 2022 FinancialContent

Its flagship vaccine product isn't selling as much as it used to.

Twitter To $50? Here Are 5 Other Price Target Changes For Wednesday
10 Aug, 2022 FinancialContent

Wedbush boosted the price target on Twitter, Inc. (NYSE: TWTR) from $30 to $50. Wedbush analyst Daniel Ives maintained the stock ...

Get ready for more merger mania in the pharma sector for the rest of the year
09 Aug, 2022 Yahoo! Finance

Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.

Why BioNTech Was Tumbling Again Today
09 Aug, 2022 FinancialContent

Fresh analyst price target cuts dampen investor sentiment on the biotech stock.

Get ready for more merger mania in pharma sector the rest of the year
09 Aug, 2022 FinancialContent

Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.

BioNTech Whale Trades For August 09
09 Aug, 2022 FinancialContent

A whale with a lot of money to spend has taken a noticeably bullish stance on BioNTech. Looking at options history for ...

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
09 Aug, 2022 Yahoo! Finance

Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

7 Blue-Chip Stocks That Will Survive 2022
09 Aug, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These are among the best blue-chip stocks to buy now. Here's why ABBV, BDX, CI, DD, MMM, JPM, and PFE can make great investments. The post 7 Blue-Chip Stocks That Will Survive 2022 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Company News for Aug 9, 2022
09 Aug, 2022 Yahoo! Finance

Companies in The News Are: GOLD,HE,BNTX,VTRS

China closes Tibet’s Potala Palace over COVID outbreak, and Novavax stock is slammed by weak earnings and halving of sales guidance
09 Aug, 2022 FinancialContent

Chinese authorities have closed Tibet's Potala Palace after a small outbreak of COVID cases in the Himalayan region, the Associated Press reported Tuesday.

Is BioNTech SE's (NASDAQ:BNTX) Latest Stock Performance A Reflection Of Its Financial Health?
09 Aug, 2022 Yahoo! Finance

Most readers would already be aware that BioNTech's (NASDAQ:BNTX) stock increased significantly by 17% over the past...

UPDATE 1-EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
09 Aug, 2022 Yahoo! Finance

The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday. The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe. A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
09 Aug, 2022 FinancialContent

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. TOP Financial ...

Fear & Greed Index Remains In 'Neutral' Zone As Investors Await Wednesday's Inflation Report
09 Aug, 2022 FinancialContent

The U.S. stock markets remained in the "neutral" zone on Tuesday, according to the CNN Money Fear and Greed index. Wall ...

BioNTech Dives As Pfizer Partner Reports Lagging Covid Vaccine Sales, Guidance
08 Aug, 2022 Yahoo! Finance

BioNTech lagged second-quarter expectations and issued light 2022 guidance on Monday, leading BNTX stock to dive.

Dow Wavered, Nvidia Slumped, Tesla Popped — and What Else Happened in the Stock Market Today
08 Aug, 2022 Yahoo! Finance

A stronger-than-expected jobs number on Friday has investors questioning the pace of rate hikes from the Federal Reserve as the central bank aims to cool inflation.

BioNTech SE (BNTX) Q2 2022 Earnings Call Transcript
08 Aug, 2022 FinancialContent

BNTX earnings call for the period ending June 30, 2022.

Here's What's Going On With Novavax Shares
08 Aug, 2022 FinancialContent

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 3.05% to $58.43 Monday afternoon in sympathy with BioNTech SE - ADR (NASDAQ: ...

BioNTech SE (BNTX) is a NASDAQ Common Stock listed in , ,

970x250